Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

Clinical Pharmacokinetics

Volumn 40, Issue 6, 2001, Pages 411-426

  Andersson, T ^a   Hassan Alin, M ^b   Hasselgren, G ^b   Rohss K ^b   Weidolf, L ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG METABOLISM; ELDERLY CARE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; LIVER FUNCTION; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0034935013     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140060-00003     Document Type: Review

References (20)

1. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole
2. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status
3. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
4. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
5. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
6. Effect of omeprazole - A gastric proton pump inhibitor - On pentagastrin stimulated acid secretion in man
7. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
8. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
9. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
10. Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E) [study no. SH-QBE-0002]
11. 14C]omeprazole in patients with impaired renal function
12. Esomeprazole pharmacokinetics are not affected by age: An assessment in the elderly
13. Pharmacokinetics of esomeprazole in patients with liver cirrhosis
14. Gender effects in pharmacokinetics and pharmacodynamics
15. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism